Inno4Vac is a public-private partnership that addresses scientific bottlenecks in vaccine development.
It proposes to develop predictive biological and mathematical models of vaccine performance and bio-manufacturing.
Artificial intelligence combined with big data and computational modelling will be used to build an open-access and cloud-based platform for in silico vaccine efficacy assessment and development. Controlled human infection models and cell-based human in vitro 3D models will be developed to enable early evaluation of vaccine efficacy and prediction of immune protection.
Finally, for vaccine bio-manufacturing the goal is to establish an open source in silico simulation platform for guiding the production of vaccine candidates and associated stability testing.
At a glance
innovations to accelerate vaccine development and manufacture
TIMELINE
01/09/2021 to 28/02/2027
COORDINATOR
European Vaccine Initiative (EVI)
FUNDER
Innovative Medicines Initiative 2 (IMI2)
FUNDING
Public-private partnership
€ 38.5 M
(€18.6M IMI, €19.9M EFPIA)
Discover how Inno4vac Subtopic 4 partners are building a modular, all-in-one computational platform for in silico (computer-based) modelling of vaccine biomanufacturing and stability testing. Learn about the process, the latest progress, the team behind the work, and what’s coming next.
